CN113226302B - 用于治疗或预防痛风或高尿酸血症的化合物的晶型 - Google Patents

用于治疗或预防痛风或高尿酸血症的化合物的晶型 Download PDF

Info

Publication number
CN113226302B
CN113226302B CN201980080515.8A CN201980080515A CN113226302B CN 113226302 B CN113226302 B CN 113226302B CN 201980080515 A CN201980080515 A CN 201980080515A CN 113226302 B CN113226302 B CN 113226302B
Authority
CN
China
Prior art keywords
compound
crystal form
crystalline
dibromo
benzofuran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980080515.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN113226302A (zh
Inventor
颜顺启
叶立天
李征
王瑞平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Ruianbo Pharmaceutical Technology Co ltd
Original Assignee
Guangzhou Ruianbo Pharmaceutical Technology Co ltd
Arthrosi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Ruianbo Pharmaceutical Technology Co ltd, Arthrosi Therapeutics Inc filed Critical Guangzhou Ruianbo Pharmaceutical Technology Co ltd
Publication of CN113226302A publication Critical patent/CN113226302A/zh
Application granted granted Critical
Publication of CN113226302B publication Critical patent/CN113226302B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980080515.8A 2018-12-06 2019-12-05 用于治疗或预防痛风或高尿酸血症的化合物的晶型 Active CN113226302B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018119567 2018-12-06
CNPCT/CN2018/119567 2018-12-06
PCT/US2019/064784 WO2020118113A1 (en) 2018-12-06 2019-12-05 Crystalline forms of a compound for treating or preventing gout or hyperuricemia

Publications (2)

Publication Number Publication Date
CN113226302A CN113226302A (zh) 2021-08-06
CN113226302B true CN113226302B (zh) 2023-08-18

Family

ID=70974392

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980080515.8A Active CN113226302B (zh) 2018-12-06 2019-12-05 用于治疗或预防痛风或高尿酸血症的化合物的晶型

Country Status (12)

Country Link
US (2) US12145917B2 (cg-RX-API-DMAC7.html)
EP (1) EP3890723A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022511800A (cg-RX-API-DMAC7.html)
KR (1) KR102946486B1 (cg-RX-API-DMAC7.html)
CN (1) CN113226302B (cg-RX-API-DMAC7.html)
AU (1) AU2019394974B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010708A2 (cg-RX-API-DMAC7.html)
EA (1) EA202191545A1 (cg-RX-API-DMAC7.html)
IL (1) IL283663B2 (cg-RX-API-DMAC7.html)
SG (1) SG11202105745UA (cg-RX-API-DMAC7.html)
TW (1) TWI828817B (cg-RX-API-DMAC7.html)
WO (1) WO2020118113A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170110083A (ko) 2014-12-23 2017-10-10 인털렉츄얼 프라퍼티 어쏘시에이츠, 엘엘씨 경피 투여를 위한 방법 및 제형
AU2017298142B2 (en) 2016-07-18 2021-11-11 Arthrosi Therapeutics, Inc. Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
EP4324460A3 (en) 2017-09-15 2024-04-24 Dyve Biosciences, Inc. Sodium bicarbonate for use in the treatment of gout and related disorders
CN113164439A (zh) 2018-12-06 2021-07-23 安索治疗公司 用于治疗或预防痛风或高尿酸血症的方法
JP2022511800A (ja) 2018-12-06 2022-02-01 アースローシ セラピューティクス,インク. 痛風または高尿酸血症を処置または予防するための化合物の結晶形態
CA3140412A1 (en) * 2019-05-14 2020-11-19 Arthrosi Therapeutics, Inc. Compound for treating gout or hyperuricemia
KR20230024354A (ko) * 2020-06-10 2023-02-20 아쓰로시 테라퓨틱스, 인크. 만성 신장 질환을 치료 또는 예방하는 방법
WO2023098872A1 (en) * 2021-12-02 2023-06-08 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
WO2023125667A1 (en) * 2021-12-30 2023-07-06 Arthrosi Therapeutics, Inc. Preparation of a compound for the treatment of gout or hyperuricemia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104311516A (zh) * 2014-09-16 2015-01-28 东北制药集团股份有限公司 一种苯溴马隆晶型b及其制备方法
CN104736178A (zh) * 2012-06-04 2015-06-24 药品循环公司 布鲁顿酪氨酸激酶抑制剂的晶形
WO2018017368A1 (en) * 2016-07-18 2018-01-25 Arthrosi Therapeutics, Llc Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
CZ282760B6 (cs) 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
WO1994008568A1 (fr) 1992-10-16 1994-04-28 Nippon Shinyaku Co., Ltd. Procede pour fabriquer des matrices de cire
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
DE19624292A1 (de) 1996-06-18 1998-01-02 Merckle Gmbh Verfahren und Zwischenprodukte zur Herstellung von 1'-Hydroxybenzbromaron
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
EP1767531A4 (en) 2004-06-10 2011-01-05 Torii Pharmaceutical Co Ltd 6-HYDROXYBENZBROMARONE OR SALTING MEDICAL COMPOSITIONS CONTAINING THEREOF
US20080305169A1 (en) 2006-05-26 2008-12-11 Japan Tobacco Inc. Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
EP2139848A1 (en) 2007-04-26 2010-01-06 Auspex Pharmaceuticals, Inc. Deuterium labelled ketamine
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
EP2291189B1 (en) 2008-05-22 2014-10-01 AstraZeneca AB Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
JP5325065B2 (ja) 2009-09-30 2013-10-23 株式会社富士薬品 新規フェノール誘導体
IT1400609B1 (it) 2010-05-10 2013-06-14 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e metformina e loro uso.
US10005750B2 (en) 2010-10-06 2018-06-26 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
US20150031768A1 (en) 2011-08-19 2015-01-29 The Trustees Of Princeton University C-halogen bond formation
US9060987B2 (en) * 2011-11-04 2015-06-23 Cymabay Therapeutics, Inc. Methods for treating gout flares
US9962362B2 (en) 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
WO2014113407A2 (en) 2013-01-16 2014-07-24 Children's Hospital Medical Center Use of small molecule inhibitors targeting eya tyrosine phosphatase
WO2014149789A1 (en) 2013-03-15 2014-09-25 Janssen Pharmaceutica Nv Combination of canagliflozin and probenecid for the treament of hyperuricemia
JP2016520133A (ja) 2013-05-31 2016-07-11 タケダ ファーマシューティカルズ ユー.エス.エー. インコーポレイティド キサンチンオキシダーゼ阻害剤を用いた治療方法及びそれを含む組成物
WO2015134467A1 (en) 2014-03-05 2015-09-11 The Trustees Of Princeton University Methods and compositions for direct radioactive labeling of bio-active molecules and building blocks
US9546166B2 (en) 2014-07-31 2017-01-17 Merck Patent Gmbh Indolizine derivatives and their use in neurodegenerative diseases
CN104262305B (zh) * 2014-09-16 2016-06-08 东北制药集团股份有限公司 一种苯溴马隆晶型a及其制备方法
WO2018090921A1 (zh) 2016-11-16 2018-05-24 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
WO2018110887A1 (ko) 2016-12-14 2018-06-21 주식회사 엘지화학 헤테로 고리 화합물 및 이를 포함하는 유기 발광 소자
WO2019195118A1 (en) 2018-04-03 2019-10-10 Children's Hospital Medical Center Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension
WO2019233459A1 (zh) 2018-06-08 2019-12-12 江苏威凯尔医药科技有限公司 人表皮生长因子受体抑制剂及其制备方法和应用
WO2020070539A1 (en) 2018-10-01 2020-04-09 Astrazeneca Ab Compositions for reducing serum uric acid
JP2022511800A (ja) 2018-12-06 2022-02-01 アースローシ セラピューティクス,インク. 痛風または高尿酸血症を処置または予防するための化合物の結晶形態
CN113164439A (zh) 2018-12-06 2021-07-23 安索治疗公司 用于治疗或预防痛风或高尿酸血症的方法
US11365189B2 (en) 2019-04-25 2022-06-21 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of tyrosine kinase
CA3140412A1 (en) 2019-05-14 2020-11-19 Arthrosi Therapeutics, Inc. Compound for treating gout or hyperuricemia
CN112079830B (zh) 2019-06-14 2023-12-22 上海翰森生物医药科技有限公司 含并环类衍生物抑制剂、其制备方法和应用
KR20230024354A (ko) 2020-06-10 2023-02-20 아쓰로시 테라퓨틱스, 인크. 만성 신장 질환을 치료 또는 예방하는 방법
CN111763215B (zh) 2020-07-21 2021-05-18 成都海博为药业有限公司 一种具有含氮杂环结构的化合物及其制备方法和用途
CN112729156A (zh) 2020-12-24 2021-04-30 上海智能制造功能平台有限公司 一种人体数字化测量装置的数据拼接及系统标定方法
CN114697265A (zh) 2020-12-29 2022-07-01 华为技术服务有限公司 一种报文处理方法及装置
WO2023028054A1 (en) 2021-08-24 2023-03-02 Arthrosi Therapeutics, Inc. Quinazoline compounds for treatment of disease
WO2023098872A1 (en) * 2021-12-02 2023-06-08 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
WO2023125667A1 (en) 2021-12-30 2023-07-06 Arthrosi Therapeutics, Inc. Preparation of a compound for the treatment of gout or hyperuricemia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104736178A (zh) * 2012-06-04 2015-06-24 药品循环公司 布鲁顿酪氨酸激酶抑制剂的晶形
CN104311516A (zh) * 2014-09-16 2015-01-28 东北制药集团股份有限公司 一种苯溴马隆晶型b及其制备方法
WO2018017368A1 (en) * 2016-07-18 2018-01-25 Arthrosi Therapeutics, Llc Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia

Also Published As

Publication number Publication date
AU2019394974A1 (en) 2021-07-15
KR20210100677A (ko) 2021-08-17
IL283663B2 (en) 2025-12-01
SG11202105745UA (en) 2021-06-29
AU2019394974B2 (en) 2025-08-28
EP3890723A1 (en) 2021-10-13
IL283663A (en) 2021-07-29
KR102946486B1 (ko) 2026-03-31
JP2025026857A (ja) 2025-02-26
US12145917B2 (en) 2024-11-19
IL283663B1 (en) 2025-08-01
US20220024889A1 (en) 2022-01-27
EP3890723A4 (en) 2022-08-03
WO2020118113A1 (en) 2020-06-11
BR112021010708A2 (pt) 2021-08-24
CN113226302A (zh) 2021-08-06
TW202039453A (zh) 2020-11-01
TWI828817B (zh) 2024-01-11
US20250059150A1 (en) 2025-02-20
CA3121913A1 (en) 2020-06-11
JP2022511800A (ja) 2022-02-01
EA202191545A1 (ru) 2021-10-28

Similar Documents

Publication Publication Date Title
US20250059150A1 (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
JP7656548B2 (ja) 痛風または高尿酸血症を処置するための化合物
JP7528080B2 (ja) 痛風または高尿酸血症を処置または予防するための方法
WO2023098872A1 (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
JP7397487B2 (ja) 感覚有毛細胞死を予防または処置するための化合物の結晶形態
CN119836422A (zh) S1p受体调节剂的结晶形式
CA3121913C (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
HK40056574A (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
HK40056574B (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
EA043666B1 (ru) Кристаллические формы соединения для лечения или профилактики подагры или гиперурикемии
HK40060723A (en) Compound for treating gout or hyperuricemia
CN119816502A (zh) Tyk2抑制剂的结晶形式
HK40056575A (en) Methods for treating or preventing gout or hyperuricemia
EA049585B1 (ru) Соединение для лечения подагры или гиперурикемии
HK40032224A (en) Crystalline forms of compounds for preventing or treating sensory hair cell death
WO2026085383A1 (en) Crystalline forms of an nlrp3 modulator

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20211208

Address after: Room 1501, No. 27, Huanyu 1st Road, Guangzhou International Biological Island, Huangpu District, Guangzhou, Guangdong

Applicant after: Guangzhou ruianbo Pharmaceutical Technology Co.,Ltd.

Address before: California, USA

Applicant before: ARTHROSI THERAPEUTICS, Inc.

TA01 Transfer of patent application right
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40056574

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant